DOCSLIB.ORG

Body Mass Index and Treatment Response to Subcutaneous Abatacept in Patients with Psoriatic Arthritis: a Iain B Mcinnes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Body Mass Index and Treatment Response to Subcutaneous Abatacept in Patients with Psoriatic Arthritis: a Iain B Mcinnes Providence St. Joseph Health Providence St. Joseph Health Digital Commons Articles, Abstracts, and Reports 1-1-2019 Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a Iain B McInnes Gianfranco Ferraccioli Maria-Antonietta D'Agostino Manuela Le Bars Subhashis Banerjee See next page for additional authors Follow this and additional works at: https://digitalcommons.psjhealth.org/publications Part of the Orthopedics Commons, and the Rheumatology Commons Recommended Citation McInnes, Iain B; Ferraccioli, Gianfranco; D'Agostino, Maria-Antonietta; Le Bars, Manuela; Banerjee, Subhashis; Ahmad, Harris A; Elbez, Yedid; and Mease, Philip, "Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a" (2019). Articles, Abstracts, and Reports. 1705. https://digitalcommons.psjhealth.org/publications/1705 This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact [email protected]. Authors Iain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, Manuela Le Bars, Subhashis Banerjee, Harris A Ahmad, Yedid Elbez, and Philip Mease This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/publications/1705 Psoriatic arthritis ORIGINAL ARTICLE Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial Iain B McInnes, 1 Gianfranco Ferraccioli, 2 Maria-Antonietta D'Agostino, 3 Manuela Le Bars,4 Subhashis Banerjee,5 Harris A Ahmad,5 Yedid Elbez,6 Philip J Mease 7 To cite: McInnes IB, ABSTRACT Key messages Ferraccioli G, D'Agostino M-A, Objective This post hoc analysis of the phase III et al. Body mass index Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) and treatment response to evaluated the effect of baseline body mass index (BMI) on What is already known about this subject? subcutaneous abatacept subsequent response to subcutaneous (SC) abatacept in ► Patients with psoriatic arthritis (PsA) tend to have in patients with psoriatic a higher body mass index (BMI) than the general arthritis: a post hoc analysis patients with psoriatic arthritis (PsA). Methods In ASTRAEA, patients with active PsA were population. A high BMI can be associated with less of a phase III trial. RMD Open favourable clinical outcomes with biologics, such as 2019;5:e000934. doi:10.1136/ randomised (1:1) to receive blinded weekly SC abatacept tumour necrosis factor inhibitors. rmdopen-2019-000934 125 mg or placebo for 24 weeks. Treatment response at week 24 was assessed by the proportions of patients What does this study add? achieving American College of Rheumatology 20% ► This analysis evaluated the relationship between Received 22 February 2019 improvement response, Disease Activity Score in 28 joints Revised 30 April 2019 BMI and treatment response to subcutaneous (SC) (DAS28 (C reactive protein (CRP))) ≤3.6 and <2.6, Health abatacept in patients with PsA. Accepted 3 May 2019 Assessment Questionnaire-Disability Index reduction ► Obese and overweight patients with PsA had a sta- from baseline ≥0.35 and radiographic non-progression tistically similar treatment response to SC abatacept (defined as change from baseline ≤0 in PsA-modified total compared with patients who were underweight or Sharp/van der Heijde score). Responses were stratified by had normal BMI. baseline BMI (underweight/normal, <25 kg/m2; overweight, 25–30 kg/m2; obese, >30 kg/m2) and compared in How might this impact on clinical practice or univariate and multivariate models. future developments? Results Of 212/213 and 210/211 patients with ► These findings suggest that SC abatacept could be baseline BMI data in the abatacept and placebo groups, considered for patients with PsA irrespective of BMI respectively, 15% and 19% were underweight/normal, status. 36% and 27% were overweight, and 49% and 54% were obese. After adjusting for baseline characteristics, there were no significant differences for any outcome measure at week 24 with abatacept in the overweight or obese necrosis factor inhibitors (TNFis), a class of versus underweight/normal subgroup. In the placebo biologic (b) disease-modifying antirheumatic group, patients in the obese versus underweight/normal drugs (DMARDs), are an effective treatment subgroup were significantly less likely to achieve DAS28 (CRP) <2.6 at week 24 (OR 0.26; 95% CI 0.08 to 0.87; option for PsA; however, a meta-analysis of 20 p=0.03). randomised clinical trials and 34 observational Conclusion BMI does not impact clinical or radiographic studies in patients with rheumatic diseases, response to SC abatacept in patients with PsA. including PsA, concluded that obesity is associ- © Author(s) (or their Trial registration number NCT01860976. employer(s)) 2019. Re-use ated with reduced treatment response to TNFis permitted under CC BY-NC. No in these patients.2 The effect of obesity on the commercial re-use. See rights and permissions. Published efficacy of bDMARDs with other mechanisms by BMJ. INTRODUCTION of action is unclear. An understanding of the For numbered affiliations see Patients with psoriatic arthritis (PsA) are potential impact of BMI on treatment-related end of article. twice as likely as the general population to be outcomes in PsA is important for informing clinical decision-making in practice; therefore, Correspondence to obese, as defined by body mass index (BMI) 2 Iain B McInnes; ≥30 kg/m , with a prevalence of obesity information on the effect of obesity on the effi- iain. mcinnes@ glasgow. ac. uk among patients with PsA of 37%.1 Tumour cacy of non-TNFi bDMARDs for PsA is needed. McInnes IB, et al. RMD Open 2019;5:e000934. doi:10.1136/rmdopen-2019-000934 1 RMD Open Abatacept is a cytotoxic T lymphocyte-associated anti- baseline ≥0.35). Structural damage was assessed by deter- gen-4-immunoglobulin fusion molecule that selectively mining the rates of radiographic non-progression (defined modulates T-cell co-stimulation and activation through the as change from baseline ≤0 in PsA-modified total Sharp/ inhibition of the CD80/CD86:CD28 co-stimulatory signal. van der Heijde score). T-cell-driven pathways are implicated in the pathogenesis of immunological diseases including PsA, making abatacept a Statistical analyses plausible therapeutic candidate.3 Indeed, abatacept, avail- Baseline patient demographics and disease characteris- able as an intravenous or subcutaneous (SC) formulation, tics were analysed descriptively according to the baseline is approved for the treatment of moderate-to-severe rheu- BMI subgroup (percentage for categorical variables and matoid arthritis (RA), juvenile idiopathic arthritis and PsA.4 mean (SD) for continuous variables). Rates for treatment Evidence from interventional trials and real-world studies response and radiographic non-progression in each BMI has shown that BMI does not affect treatment response to subgroup were determined at week 24 and compared abatacept in patients with RA.5 6 However, there are limited between subgroups using univariable and multivariable data on the impact of BMI on response to abatacept in analyses with the underweight/normal BMI subgroup patients with PsA. as the reference. Key potential confounding factors for In the randomised, double-blind, placebo-controlled, treatment efficacy were included in the multivariable international phase III Active PSoriaTic Arthritis RAndom- model. Results are presented as ORs with corresponding izEd TriAl (ASTRAEA), the American College of Rheu- 95% CIs; p values were calculated for each treatment matology 20% improvement (ACR20) response rate in outcome by BMI subgroup, based on a logistic regression patients with PsA at week 24 was significantly higher with model. The ORs were statistically significant when the abatacept versus placebo.7 Here, we present findings from 95% CIs did not cross 1. An additional stratified multi- an analysis of ASTRAEA to explore the impact of patient variable analysis was performed to evaluate treatment BMI at baseline on the response to SC abatacept. responses by baseline BMI subgroup at week 24, (i) in patients who received abatacept without any concomitant METHODS non-bDMARD (defined as not receiving any of actarit, Study design and treatment apremilast, auranofin, aurothioglucose, aurotioprol, A post hoc analysis of the ASTRAEA study was conducted aurotioprol gold salt, azathioprine, bucillamine, chloram- to evaluate the effect of baseline BMI on the response bucil, chloroquine, cyclosporine, gold salts, gold sodium to SC abatacept in patients with PsA. The study design, thiomalate, hydroxychloroquine, leflunomide, loben- ethics approvals, study population, patient eligibility zarit, methotrexate, mizoribine, penicillamine, sulfasala- criteria and main endpoints of ASTRAEA have been zine, tiopronin or tofacitinib); concomitant NSAIDs, oral reported previously.7 The trial is registered at www. clin- corticosteroids or topical corticosteroids were permitted, icaltrials. gov. and (ii) in those who received abatacept in combination Briefly, patients with active PsA and an inadequate with a non-bDMARD. response or intolerance to ≥1 non-bDMARD were randomised (1:1) to receive blinded weekly SC abatacept RESULTS 125 mg or placebo for 24 weeks.
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • ¬Chronic Immune-Mediated Inflammatory Diseases And
    The Association Between Chronic Immune-Mediated Inflammatory Diseases and Cardiovascular Risk Jose Miguel Baena-Díez1,2,3, Maria Garcia-Gil4,5,6, Marc Comas-Cufí4,5, Rafel Ramos4,5,6,7, Daniel Prieto-Alhambra8,9, Betlem Salvador-González1,10, Roberto Elosua1, Irene R. Dégano1, Judith Peñafiel1, Maria Grau1,11* 1REGICOR Study Group - Cardiovascular Epidemiology and Genetics, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain 2La Marina Primary Care Centre and Primary Care Research Institute Jordi Gol, Catalan Institute of Health, Barcelona, Spain 3Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Spain 4Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Spain 5ISV Research Group, Research Unit in Primary Care, Primary Care Services, Girona, Catalan Institute of Health (ICS), Spain 6TransLab Research Group, Department of Medical Sciences, School of Medicine, University of Girona, Girona, Spain 7Biomedical Research Institute, Girona (IdIBGi), ICS, Spain 8Musculoskeletal diseases Research Group (GREMPAL), Primary Care Research Institute Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain 9Musculoskeletal Pharmaco- and Device Epidemiology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom 10Florida Sud Primary Care Centre and Primary Care Research Institute Jordi Gol, Catalan Institute of Health, L’Hospitalet de Llobregat, Spain 11University of Barcelona, Spain *Corresponding
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • WO 2012/175518 Al 27 December 2012 (27.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/175518 Al 27 December 2012 (27.12.2012) P O P C T (51) International Patent Classification: (72) Inventor; and A61K 39/39 (2006.01) A61K 39/205 (2006.01) (75) Inventor/Applicant (for US only): PETROVSKY, A61K 31/715 (2006.01) A61K 39/29 (2006.01) Nikolai [AU/AU]; 11 Walkley Avenue, Warradale, A d A61K 39/145 (2006.01) elaide, South Australia 5046 (AU). (21) International Application Number: (74) Agent: WRIGHT,, Andrew John; POTTER CLARKSON PCT/EP2012/061748 LLP, Park View House, 58 The Ropewalk, Nottingham Nottinghamshire NG1 5DD (GB). (22) International Filing Date: 19 June 2012 (19.06.2012) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) English Filing Language: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (30) Priority Data: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 61/498,557 19 June 201 1 (19.06.201 1) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (71) Applicant (for all designated States except US): VAXINE MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PTY LTD [AU/AU]; Endocrinology Department, Room OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 6D313, Flinders Medical Centre, Bedford Park, South SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, Australia 5042 (AU).
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Silver and Gold Coating
    Copyright © Tarek Kakhia. All rights reserved. http://tarek.kakhia.org Gold & Silver Coatings By A . T . Kakhia 1 Copyright © Tarek Kakhia. All rights reserved. http://tarek.kakhia.org 2 Copyright © Tarek Kakhia. All rights reserved. http://tarek.kakhia.org Part One General Knowledge 3 Copyright © Tarek Kakhia. All rights reserved. http://tarek.kakhia.org 4 Copyright © Tarek Kakhia. All rights reserved. http://tarek.kakhia.org Aqua Regia ( Royal Acid ) Freshly prepared aqua regia is colorless, Freshly prepared aqua but it turns orange within seconds. Here, regia to remove metal fresh aqua regia has been added to these salt deposits. NMR tubes to remove all traces of organic material. Contents 1 Introduction 2 Applications 3 Chemistry 3.1 Dissolving gold 3.2 Dissolving platinum 3.3 Reaction with tin 3.4 Decomposition of aqua regia 4 History 1 - Introduction Aqua regia ( Latin and Ancient Italian , lit. "royal water"), aqua regis ( Latin, lit. "king's water") , or nitro – hydro chloric acid is a highly corrosive mixture of acids, a fuming yellow or red solution. The mixture is formed by freshly mixing concentrated nitric acid and hydro chloric acid , optimally in a volume ratio of 1:3. It was named 5 Copyright © Tarek Kakhia. All rights reserved. http://tarek.kakhia.org so because it can dissolve the so - called royal or noble metals, gold and platinum. However, titanium, iridium, ruthenium, tantalum, osmium, rhodium and a few other metals are capable of with standing its corrosive properties. IUPAC name Nitric acid hydro chloride Other names aqua regia , Nitro hydrochloric acid Molecular formula HNO3 + 3 H Cl Red , yellow or gold Appearance fuming liquid 3 Density 1.01–1.21 g / cm Melting point − 42 °C Boiling point 108 °C Solubility in water miscible in water Vapor pressure 21 mbar 2 – Applications Aqua regia is primarily used to produce chloro auric acid, the electrolyte in the Wohl will process.
    [Show full text]
  • Chronic Immune-Mediated Inflammatory Diseases
    Supplementary Table 1 Diagnoses included in each group ICD-10 Code Title K50-K52 Inflammatory bowel diseases K50 Crohn disease (regional enteritis) K51 Ulcerative colitis K52 Other noninfective gastroenteritis and colitis M05-M14, L40.5 Inflammatory polyarthropathies M05 Seropositive rheumatoid arthritis M06 Other rheumatoid arthritis M07 Psoriatic and enteropathic arthropathies M08 Juvenile arthritis M09 Juvenile arthritis in diseases classified elsewhere M10 Gout M11 Other crystal arthropathies M12 Other specific arthropathies M13 Other arthritis L40.5 Arthropathic psoriasis M30-M35, G635 Systemic connective tissue disorders M30 Polyarteritis nodosa and related conditions M31 Other necrotizing vasculopathies M32 Systemic lupus erythematosus M33 Dermatopolymyositis M34 Systemic sclerosis M35 Other systemic involvement of connective tissue G63.5 Polyneuropathy in systemic connective tissue disorders M45-M46 Spondylopathies M45 Ankylosing spondylitis M46 Other inflammatory spondylopathies Supplementary Table 2 Outcomes considered in the follow-up ICD-10 Code Title I20-I23, I25 Ischemic heart diseases I20 Angina pectoris I21 Acute myocardial infarction I22 Subsequent myocardial infarction I23 Certain current complications following acute myocardial infarction I25 Chronic ischaemic heart disease I60-I64 Cerebrovascular diseases I60 Subarachnoid hemorrhage I61 Intracerebral haemorrhage I62 Other nontraumatic intracranial haemorrhage I63 Cerebral infarction I64 Stroke, not specified as haemorrhage or infarction Supplementary Table 3 DMARDS
    [Show full text]
  • WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/20 (2006.01) A61K 31/485 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2013/06385 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, 1 July 20 13 (01 .07.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2012 70405 6 July 2012 (06.07.2012) DK (84) Designated States (unless otherwise indicated, for every 61/668,741 6 July 2012 (06.07.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: EGALET LTD.
    [Show full text]
  • Different Viewpoints on Tapering Dmards in Rheumatoid Arthritis Verschillende Perspectieven Op Het Afbouwen Van Dmards Bij Reumatoïde Artritis
    Diff erent Viewpoints on Tapering DMARDs in Rheumatoid Arthritis Diff Elise van Mulligen Diff erent Viewpoints on Tapering DMARDs in Rheumatoid Arthritis Elise van Mulligen Different Viewpoints on Tapering DMARDs in Rheumatoid Arthritis Verschillende perspectieven op het afbouwen van DMARDs bij reumatoïde artritis Elise van Mulligen Cover design: Publiss Lay-out: Publiss | www.publiss.nl Print: Ridderprint | www.ridderprint.nl. © Copyright 2021: Elise van Mulligen All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without prior permission of the author. Financial support for the publication of this thesis was kindly provided by the Erasmus University Medical Center, Pfizer B.V., Eli Lilly Nederland B.V., and Galapagos B.V.. Different Viewpoints on Tapering DMARDs in Rheumatoid Arthritis Verschillende perspectieven op het afbouwen van DMARDs bij reumatoïde artritis Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof. dr. F.A. van der Duijn Schouten en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op dinsdag 2 maart 2021 om 15:30 uur door Elise van Mulligen geboren te Utrecht. Promotiecommissie: Promotoren: prof. dr. J.M.W. Hazes prof. dr. A.H.M. van der Helm - van Mil prof. dr. A.E.A.M. Weel Overige leden: prof. dr. A.H.J. Mathijssen prof. dr. C.J. van der Woude dr. A.A. den Broeder Copromotor: dr. P.H.P. de Jong Table of contents Chapter
    [Show full text]
  • Body Mass Index and Treatment Response to Subcutaneous Abatacept in Patients with Psoriatic Arthritis: a Post Hoc Analysis of a Phase III Trial
    Psoriatic arthritis RMD Open: first published as 10.1136/rmdopen-2019-000934 on 30 May 2019. Downloaded from ORIGINAL ARTICLE Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial Iain B McInnes, 1 Gianfranco Ferraccioli, 2 Maria-Antonietta D'Agostino, 3 Manuela Le Bars,4 Subhashis Banerjee,5 Harris A Ahmad,5 Yedid Elbez,6 Philip J Mease 7 To cite: McInnes IB, ABSTRACT Key messages Ferraccioli G, D'Agostino M-A, Objective This post hoc analysis of the phase III et al. Body mass index Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) and treatment response to evaluated the effect of baseline body mass index (BMI) on What is already known about this subject? subcutaneous abatacept subsequent response to subcutaneous (SC) abatacept in ► Patients with psoriatic arthritis (PsA) tend to have in patients with psoriatic a higher body mass index (BMI) than the general arthritis: a post hoc analysis patients with psoriatic arthritis (PsA). Methods In ASTRAEA, patients with active PsA were population. A high BMI can be associated with less of a phase III trial. RMD Open favourable clinical outcomes with biologics, such as 2019;5:e000934. doi:10.1136/ randomised (1:1) to receive blinded weekly SC abatacept tumour necrosis factor inhibitors. rmdopen-2019-000934 125 mg or placebo for 24 weeks. Treatment response at week 24 was assessed by the proportions of patients What does this study add? copyright. achieving American College of Rheumatology 20% ► This analysis evaluated the relationship between Received 22 February 2019 improvement response, Disease Activity Score in 28 joints Revised 30 April 2019 BMI and treatment response to subcutaneous (SC) (DAS28 (C reactive protein (CRP))) ≤3.6 and <2.6, Health abatacept in patients with PsA.
    [Show full text]
  • WO 2017/120601 Al 13 July 2017 (13.07.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/120601 Al 13 July 2017 (13.07.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 39/395 (2006.01) A61P 27/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2017/012757 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, January 2017 (09.01 .2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/276,543 8 January 2016 (08.01 .2016) 62/324,708 19 April 2016 (19.04.2016) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: CLEARSIDE BIOMEDICAL, INC. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [US/US]; 1220 Old Alpharetta Road, Suite 300, Alphar- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, etta, Georgia 30005 (US).
    [Show full text]